Table 2 List of ongoing clinical trials for exploring the use of MSCs or their derivatives in the treatment of COVID-19
From: The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019
Trial ID | Title | Site | Tissue Source | No. of Patients |
|---|---|---|---|---|
ChiCTR2000029569 | Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial | China, Hubei | Conditioned Media from Umbilical Cord MSCs | 15 Control 15 Exp |
ChiCTR2000030173 | Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration | China, Hu'nan | Umbilical Cord | 30 Control 30 Exp |
ChiCTR2000030116 | Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19) | China, Jiangxi | Umbilical Cord | 16 Exp |
NCT04269525 | Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia | China, Hubei | Umbilical Cord | 10 Exp |
ChiCTR2000030138 | Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) | China, Beijing | Umbilical Cord | 30 Control 30 Exp |
ChiCTR2000029990 | Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19) | China, Beijing | Not Specified | 60 Control 60 Exp |
ChiCTR2000030088 | Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) | China, Beijing | Umbilical Cord | 20 Control 20 Exp |
ChiCTR2000030020 | The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19) | China, Hu'nan | Not Specified | 20 Exp |
ChiCTR2000030261 | A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19) | China, Jiangsu | MSC Exosomes (origin not specified) | 13 Control 13 Exp |
NCT04276987 | A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia | China, Hubei | Adipose Tissue—MSC Exosomes | 30 Exp |
ChiCTR2000030484 | HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19) | China, Hubei | Umbilical Cord + Exosomes | 30 Control 30 Exp 1 30 Exp 2 |
ChiCTR2000029580 | Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial | China, Hubei | MSCs (origin not specified) + Ruxolitinib | 35 Control 35 Exp |
ChiCTR2000030866 | Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19) | China, Hu'nan | Umbilical Cord | 30 Exp |
ChiCTR2000030835 | Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19) | China, He'nan | Umbilical Cord | 10 Exp 1 10 Exp 2 |
NCT04302519 | Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells | China, Hubei | Dental Pulp | 24 Exp |
NCT04313322 | Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells | Jordan | Umbilical Cord | 5 Exp |
ChiCTR2000031319 | Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19 | China, Hubei | Dental Pulp | 10 Control 10 Exp |
ChiCTR2000031494 | Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) | China, Hubei | Umbilical Cord | 18 Control 18 Exp |
ChiCTR2000031430 | Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19) induced pulmonary fibrosis | China, Beijing | Umbilical Cord | 100 Control 100 Exp |
ChiCTR2000029606 | Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19) | China, Zhejiang | Menstrual Blood—MSCs ± artificial liver therapy | 25 Control 18 Exp 1 10 Exp 2 10 Exp 3 |
NCT04252118 | Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19 | China, Zhejiang | Umbilical Cord | 10 Control 10 Exp |
NCT04273646 | Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19 | China, Hubei | Umbilical Cord | 24 Control 24 Exp |
NCT04288102 | Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19) | China, Hubei | Not Specified | 45 Control 45 Exp |
NCT04315987 | NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (HOPE) | Brazil, Sao Paulo | Not Specified | 66 Exp |
NCT04336254 | Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients | China, Hubei | Dental Pulp | 10 Control 10 Exp |
NCT04339660 | Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia | China, Hubei | Umbilical Cord | 15 Control 15 Exp |
NCT04341610 | ASC Therapy for Patients With Severe Respiratory COVID-19 (ASC COVID-19) | Denmark, Copenhagen | Adipose Tissue | 20 Control 20 Exp |
NCT04345601 | Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | USA, Texas | Bone Marrow | 30 Exp |
NCT04346368 | Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) | China, Guangdong | Bone Marrow | 10 Control 10 Exp |
NCT04348461 | BAttLe Against COVID-19 Using MesenchYmal Stromal Cells | Spain, Madrid | Adipose Tissue | 50 Control 50 Exp |
NCT04349631 | A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 | USA, Texas | Adipose Tissue | 56 Exp |
EUCTR2019-002688-89-ES | Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome | Spain, Bizkaia | Not Specified | 14 Control 14 Exp |
EUCTR2020-001682-36-ES | Treatment of COVID-19 with allogeneic mesenchymal cells (MSV®) | Spain, Madrid | Not Specified | 12 Control 12 Exp |
EUCTR2020-001266-11-ES | Clinical trial of administration of MSC to patients with respiratory distress type COVID-19 | Spain, Madrd | Adipose Tissue | 50 Control 50 Exp |
IRCT20140911019125N6 | The effect of dental pulp mesenchymal stem cells in treatment of corona disease | Iran | Dental Pulp | 10 Exp |
IRCT20140528017891N8 | The effect of stem cell transplantation in the treatment of COVID-19 | Iran | Umbilical Cord | 10 Exp |
IRCT20200325046860N2 | Mesenchymal Stem Cell therapy in COVID19 | Iran | Not Specified | 5 Exp |
IRCT20200217046526N1 | Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection | Iran | Not Specified | 6 Exp |
NCT03042143 | Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19) (REALIST), Phase I/II | UK, Belfast | Umbilical Cord | 9 Phase I 33 Control 33 Exp |
NCT04293692 | Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus | China, Hubei | Umbilical Cord | 12 Control 12 Exp |
NCT04352803 | Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease | USA + Spain | Adipose Tissue | 10 Control 10 Exp |
NCT04366830 | Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection | USA, New York | Not Specified | 50 Exp |
EUCTR2020-001364-29-ES | Study with stem cells from allogenic adipose tissue, in patients with coronavirus severe pneumonia | Spain, Seville | Adipose Tissue | 13 Control 13 Exp |
EUCTR2020-001505-22-ES | Efficacy and safety evaluation of umbilical cord mesenchymal stem cells for the treatment of patients with respiratory failure due to coronavirus (COVID-19) | Spain, Barcelona | Umbilical Cord | 15 Control 15 Exp |
NCT04348435 | A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 | USA, Texas | Adipose Tissue | 50 Control 50 Exp |
NCT04355728 | Use of UC-MSCs for COVID-19 Patients | USA, Florida | Umbilical Cord | 12 Control 12 Exp |
NCT04361942 | Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV) COVID_MSV | Spain, Valladolid | Not Specified | 12 Control 12 Exp |
NCT04366063 | Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome | Iran | Not Specified | 20 Control 20 Exp 1 20 Exp 2 |
NCT04371601 | Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 | China, Fujian | Umbilical Cord | 30 Control 30 Exp |
NCT04377334 | Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS) | Germany | Bone Marrow | 20 Control 20 Exp |
IRCT20200413047063N1 | Â | Iran | Â | 10 Control 10 Exp |
IRCT20200418047121N2 | Stem cell therapy in COVID-19 | Iran | Â | 3 Control 3 Exp |
NCT04366271 | Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19 MESCEL-COVID19 | Spain, Madrid | Umbilical Cord | 53 Control 53 Exp |
NCT04390139 | Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 COVIDMES | Spain, Barcelona | Umbilical Cord | 15 Control 15 Exp |
NCT04390152 | Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 | Colombia | Umbilical Cord | 20 Control 20 Exp |
NCT04392778 | Clinical Use of Stem Cells for the Treatment of Covid-19 | Turkey | Not Specified | 15 Control 15 Exp |
NCT04400032 | Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome—Vanguard CIRCA-19 | Canada | Bone Marrow | 3 Exp1 3 Exp 2 3 Exp 3 |
ACTRN12620000612910 | The MEND (MEseNchymal coviD-19) Trial: a pilot study to investigate early efficacy of mesenchymal stem cells in adults with COVID-19 | Australia | Mesenchymo-Angioblast | 12 Control 12 Exp |
NCT04382547 | Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells | Belarus | Olfactory-Mucosa | 20 Control 20 Exp |
NCT04397796 | Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation | USA, California | Bone Marrow | 23 Control 23 Exp |
NCT04416139 | Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 COVID-19 | Mexico | Umbilical Cord | 5 Control 5 Exp |
IRCT20200421047150N1 | Stem cell treatment for COVID-19 | Iran | Umbilical Cord | 45 Control 45 Exp |
IRCT20160809029275N1 | stem cell therapy in Covid-19 | Iran | Umbilical Cord | 10 Control 10 Exp |
NCT04366323 | Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 | Spain, Andalucia | Adipose Tissue | 13 Control 13 Exp |
NCT04371393 | MSCs in COVID-19 ARDS | USA, New York | Not Specified | 150 Control 150 Exp |
NCT04399889 | hCT-MSCs for COVID19 ARDS | USA, North Carolina | Umbilical Cord | 15 Control 15 Exp |
NCT04428801 | Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19 | USA, Texas | Adipose Tissue | 100 Control 100 Exp |
NCT04429763 | Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia CELMA | Colombia | Umbilical Cord | 15 Control 15 Exp |
ISRCTN33578935 | To study the treatment of COVID-19 with severe viral pneumonia by using purified stem cell exosomes | Germany | Â | 32 Control 32 Exp |
NCT04389450 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | USA, California | Â | 70 Control 70 Exp |